INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $403,000 | +6.1% | 7,405 | -61.3% | 0.00% | 0.0% |
| Q3 2020 | $380,000 | -5.5% | 19,132 | +0.1% | 0.00% | 0.0% |
| Q2 2020 | $402,000 | +75.5% | 19,116 | +2.2% | 0.00% | +100.0% |
| Q1 2020 | $229,000 | -16.4% | 18,704 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $274,000 | +9.6% | 18,704 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $250,000 | -18.3% | 18,704 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $306,000 | -4.1% | 18,704 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $319,000 | +41.2% | 18,704 | +136.3% | 0.00% | +100.0% |
| Q3 2018 | $226,000 | +4.6% | 7,914 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $216,000 | -2.3% | 7,914 | -31.3% | 0.00% | 0.0% |
| Q4 2017 | $221,000 | -22.7% | 11,516 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $286,000 | +55.4% | 11,516 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $184,000 | +13.6% | 11,516 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $162,000 | – | 11,516 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |